A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma

Chest

Volumn 144, Issue 2, 2013, Pages 411-419

  Garcia, Gilles ^a,b,c   Magnan, Antoine ^d,e,f   Chiron, Raphaël ^g   Contin Bordes, Cécile ^h,i,j   Berger, Patrick ^j,k   Taillé, Camille ^l,m   Devouassoux, Gilles ⁿ   De Blay, Frédéric ^o,p   Couderc, Louis Jean ^p   Didier, Alain ^q   O'Callaghan, Dermot S ^a,b,c   Girodet, Pierre Olivier ^k,r   Bourdeix, Isabelle ^s   Gros, Vincent Le ^s   Humbert, Marc ^a,b,c  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b BICÊTRE HOSPITAL   (France)

^c Universite Paris Sud   (France)

^d UNIVERSITÉ DE NANTES   (France)

^e L INSTITUT DU THORAX   (France)

^f NANTES UNIVERSITY HOSPITAL   (France)

^g HÔPITAL ARNAUD DE VILLENEUVE   (France)

^h CNRS Bordeaux Segalen University   (France)

ⁱ CNRS   (France)

^j BORDEAUX UNIVERSITY HOSPITAL   (France)

^k CENTRE DE RECHERCHE CARDIO THORACIQUE DE BORDEAUX   (France)

^l UNIVERSITÉ PARIS DESCARTES   (France)

^m INSERM   (France)

ⁿ UNIVERSITÉ LYON 1   (France)

^o UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^p LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^q SERVICE DE PNEUMOLOGIE   (France)

^r UNIVERSITÉ DE BORDEAUX   (France)

^s NOVARTIS PHARMA K K   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; IMMUNOGLOBULIN E RECEPTOR; OMALIZUMAB; PLACEBO;

ADULT; AGED; ARTICLE; ASTHMA; BASOPHIL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE CONTROL; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG TREATMENT FAILURE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; HUMAN CELL; MAINTENANCE THERAPY; MALE; NONATOPIC ASTHMA; PHASE 3 CLINICAL TRIAL; PLASMACYTOID DENDRITIC CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RECEPTOR AFFINITY;

EID: 84880851544     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.12-1961     Document Type: Article

References (28)

1. Rackemann FM. A working classifi cation of asthma. Am J Med. 1947; 3 (5): 601-606.
2. Humbert M, Menz G, Ying S, et al. The immunopathology of extrinsic (atopic) and intrinsic (non-atopic) asthma: more similarities than differences. Immunol Today. 1999; 20(11): 528-533.
3. Nieves A, Magnan A, Boniface S, et al; ARIA. Phenotypes of asthma revisited upon the presence of atopy. Respir Med. 2005; 99 (3): 347-354.
4. Romanet-Manent S, Charpin D, Magnan A, Lanteaume A, Vervloet D, Group EC; EGEA Cooperative Group. Allergic vs nonallergic asthma: what makes the difference? Allergy. 2002; 57 (7): 607-613.
5. Bateman ED, Hurd SS, Barnes PJ, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J. 2008; 31 (1): 143-178.
6. Wenzel S. Severe asthma in adults. Am J Respir Crit Care Med. 2005; 172 (2): 149-160.
7. Humbert M, Beasley R, Ayres J, et al. Benefi ts of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005; 60 (3): 309-316.
8. Hanania NA, Alpan O, Hamilos DL, et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med. 2011; 154 (9): 573-582.
9. Berger P, Scotto-Gomez E, Molimard M, Marthan R, Le Gros V, Tunon-de-Lara JM. Omalizumab decreases nonspecifi c airway hyperresponsiveness in vitro. Allergy. 2007; 62 (2): 154-161.
10. Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001; 108 (2): 184-190.
11. MacGlashan DW Jr, Bochner BS, Adelman DC, et al. Downregulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol. 1997; 158 (3): 1438-1445.
12. Djukanović R, Wilson SJ, Kraft M, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway infl ammation in allergic asthma. Am J Respir Crit Care Med. 2004; 170 (6): 583-593.
13. Prussin C, Griffi th DT, Boesel KM, Lin H, Foster B, Casale TB. Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. J Allergy Clin Immunol. 2003; 112 (6): 1147-1154.
14. Chanez P, Contin-Bordes C, Garcia G, et al. Omalizumabinduced decrease of Fc RI expression in patients with severe allergic asthma. Respir Med. 2010; 104 (11): 1608-1617.
15. Humbert M, Durham SR, Ying S, et al. IL-4 and IL-5 mRNA and protein in bronchial biopsies from patients with atopic and nonatopic asthma: evidence against "intrinsic" asthma being a distinct immunopathologic entity. Am J Respir Crit Care Med. 1996; 154 (5): 1497-1504.
16. Humbert M, Durham SR, Kimmitt P, et al. Elevated expression of messenger ribonucleic acid encoding IL-13 in the bronchial mucosa of atopic and nonatopic subjects with asthma. J Allergy Clin Immunol. 1997; 99 (5): 657-665.
17. Ying S, Humbert M, Barkans J, et al. Expression of IL-4 and IL-5 mRNA and protein product by CD4 1 and CD8 1 T cells, eosinophils, and mast cells in bronchial biopsies obtained from atopic and nonatopic (intrinsic) asthmatics. J Immunol. 1997; 158 (7): 3539-3544.
18. Humbert M, Grant JA, Taborda-Barata L, et al. High-affi nity IgE receptor (FcepsilonRI)-bearing cells in bronchial biopsies from atopic and nonatopic asthma. Am J Respir Crit Care Med. 1996; 153 (6 pt 1): 1931-1937.
19. Ying S, Humbert M, Meng Q, et al. Local expression of epsilon germline gene transcripts and RNA for the epsilon heavy chain of IgE in the bronchial mucosa in atopic and nonatopic asthma. J Allergy Clin Immunol. 2001; 107 (4): 686-692.
20. Takhar P, Corrigan CJ, Smurthwaite L, et al. Class switch recombination to IgE in the bronchial mucosa of atopic and nonatopic patients with asthma. J Allergy Clin Immunol. 2007; 119 (1): 213-218.
21. Balzar S, Strand M, Rhodes D, Wenzel SE. IgE expression pattern in lung: relation to systemic IgE and asthma phenotypes. J Allergy Clin Immunol. 2007; 119 (4): 855-862.
22. Mouthuy J, Detry B, Sohy C, Pirson F, Pilette C. Presence in sputum of functional dust mite-specifi c IgE antibodies in intrinsic asthma. Am J Respir Crit Care Med. 2011; 184 (2): 206-214.
23. Bhat KD, Calhoun WJ. Omalizumab in asthma: is the therapeutic window too small? Chest. 2011; 139 (1): 8-10.
24. van den Berge M, Pauw RG, de Monchy JG, van Minnen CA, Postma DS, Kerstjens HA. Benefi cial effects of treatment with anti-IgE antibodies (Omalizumab) in a patient with severe asthma and negative skin-prick test results. Chest. 2011; 139(1): 190-193.
25. Menzella F, Piro R, Facciolongo N, Castagnetti C, Simonazzi A, Zucchi L. Long-term benefi ts of omalizumab in a patient with severe non-allergic asthma. Allergy Asthma Clin Immunol. 2011; 7 (1): 9.
26. Zureik M, Neukirch C, Leynaert B, Liard R, Bousquet J, Neukirch F; European Community Respiratory Health Survey. Sensitisation to airborne moulds and severity of asthma: cross sectional study from European Community respiratory health survey. BMJ. 2002; 325 (7361): 411-414.
27. Bachert C, van Steen K, Zhang N, et al. Specifi c IgE against Staphylococcus aureus enterotoxins: an independent risk factor for asthma. J Allergy Clin Immunol. 2012; 130(2): 376-381., e8.
28. de Llano LP, Vennera MD, Alvarez FJ, et al; the Spanish Registry. Effects of omalizumab in nonatopic asthma: results from a Spanish multicenter registry. J Asthma. 2013; 50 (3): 296-301.